mTORC1 Signaling: A Double-Edged Sword in Diabetic β Cells

Slides:



Advertisements
Similar presentations
Specialized signaling pathways 1: RTK associated pathways
Advertisements

The nature, significance, and glucagon-like peptide-1 analog treatment of brain insulin resistance in Alzheimer's disease  Konrad Talbot, Hoau-Yan Wang 
AMPK—Sensing Energy while Talking to Other Signaling Pathways
by Rogelio Zamilpa, and Merry L. Lindsey
mTOR Signaling in Growth Control and Disease
Aspirin use and endometrial cancer risk and survival
IRS-1: Auditing the effectiveness of mTOR inhibitors
AMPK-Dependent Phosphorylation of ULK1 Induces Autophagy
Figure 1 mTOR pathway activation
The Akt-mTOR tango and its relevance to cancer
Volume 140, Issue 7, Pages (June 2011)
Kinase inhibitors: Vice becomes virtue
Overgrowth Syndromes Caused by Somatic Variants in the Phosphatidylinositol 3- Kinase/AKT/Mammalian Target of Rapamycin Pathway  Gozde Akgumus, Fengqi.
Pascal Ferré, Fabienne Foufelle  Cell Metabolism 
mTORC1: Turning Off Is Just as Important as Turning On
Nat. Rev. Endocrinol. doi: /nrendo
Figure 3 Physiological regulation of autophagy in the heart
Alexander L. Fogel, BS, Sharleen Hill, MD, Joyce M.C. Teng, MD, PhD 
Figure 1 mTOR complex biology
Review AMP-activated protein kinase: Ancient energy gauge provides clues to modern understanding of metabolism CELL METABOLISM : JANUARY 2005 · VOL.
Volume 29, Issue 3, Pages (March 2016)
The pathway signalling starts with the binding of insulin or growth factors to insulin receptors. The pathway signalling starts with the binding of insulin.
Development of PI3K/AKT/mTOR Pathway Inhibitors and Their Application in Personalized Therapy for Non–Small-Cell Lung Cancer  Vassiliki Papadimitrakopoulou,
Maria M. Mihaylova, David M. Sabatini, Ömer H. Yilmaz  Cell Stem Cell 
Identification of TOR Signaling Complexes
Is REDD1 a Metabolic Éminence Grise?
PTEN Enters the Nuclear Age
Figure 1 The insulin signalling pathway
Inhibition of mammalian target of rapamycin: Two goals with one shot?
Rapamycin: One Drug, Many Effects
Taru Muranen, Funda Meric-Bernstam, Gordon B. Mills  Cancer Cell 
Autophagy: A Sweet Process in Diabetes
The PI3K Pathway in Human Disease
FGFR Signaling as a Target for Lung Cancer Therapy
Autophagy: A Potential Link between Obesity and Insulin Resistance
mTORC1 signalling links cellular growth with autophagy
Autophagy in kidney disease and aging: lessons from rodent models
IRS-1: Auditing the effectiveness of mTOR inhibitors
An Emerging Role of mTOR in Lipid Biosynthesis
AMPK—Sensing Energy while Talking to Other Signaling Pathways
Metabolic Control of Autophagy
Evelyn E. Telfer, Ph.D., F.S.B., Mary B. Zelinski, Ph.D. 
Russell G. Jones, Edward J. Pearce  Immunity 
Volume 18, Issue 1, Pages (July 2013)
Live Longer sans the AT1A Receptor
Estrogen Receptors and the Metabolic Network
AKT/PKB Signaling: Navigating the Network
Figure 1 The mTOR signalling pathway
Pierre Theurey, Jennifer Rieusset  Trends in Endocrinology & Metabolism 
AKT/PKB Signaling: Navigating Downstream
A Ceramide-Centric View of Insulin Resistance
AMP-activated protein kinase: Ancient energy gauge provides clues to modern understanding of metabolism  Barbara B. Kahn, Thierry Alquier, David Carling,
Rapamycin: One Drug, Many Effects
mTOR and Akt Signaling in Cancer: SGK Cycles In
Metabolic Regulation by p53 Family Members
Alex Kentsis, A. Thomas Look  Cell Stem Cell 
Simon Ekman, MD, PhD, Murry W. Wynes, PhD, Fred R. Hirsch, MD, PhD 
Brian K. Kennedy, Dudley W. Lamming  Cell Metabolism 
The nature, significance, and glucagon-like peptide-1 analog treatment of brain insulin resistance in Alzheimer's disease  Konrad Talbot, Hoau-Yan Wang 
Sestrins Orchestrate Cellular Metabolism to Attenuate Aging
Tobias B. Huber, Gerd Walz, E Wolfgang Kuehn  Kidney International 
Role reversal: Brain insulin and liver STAT3
Autophagy in the Cellular Energetic Balance
Dysregulation of the mTOR Pathway Secondary to Mutations or a Hostile Microenvironment Contributes to Cancer and Poor Wound Healing  Richard A.F. Clark,
Lysosomal Rag-ulation of mTOR Complex 1 Activity
Nutrient Sensing, Metabolism, and Cell Growth Control
UPR and cross-talk between apoptosis and metabolism.
Connections between insulin/insulin-like growth factor 1 signaling and metabolic pathways in tumor cells. Connections between insulin/insulin-like growth.
The Ribosome and TORC2: Collaborators for Cell Growth
Presentation transcript:

mTORC1 Signaling: A Double-Edged Sword in Diabetic β Cells Amin Ardestani, Blaz Lupse, Yoshiaki Kido, Gil Leibowitz, Kathrin Maedler  Cell Metabolism  Volume 27, Issue 2, Pages 314-331 (February 2018) DOI: 10.1016/j.cmet.2017.11.004 Copyright © 2017 Elsevier Inc. Terms and Conditions

Figure 1 A Simplified Presentation of mTOR Signaling under Physiological Conditions The mTOR pathway integrates nutrient and growth factor signaling to regulate cellular metabolism, growth, and survival. In response to cellular stimulation by mitogens (such as insulin or IGF1), PI3K generates PIP3, which promotes the activation of mTORC2 and AKT. AKT phosphorylates and inhibits the upstream inhibitor of mTORC1, known as TSC1/2, leading to GTPase Rheb stimulation and mTORC1 activation. Also, nutrients such as amino acids and glucose function through the Rag family of GTPases to activate mTORC1 by localizing mTORC1 to the lysosome. Under high-energy conditions (high ATP:ADP ratio), AMPK is inhibited, and thus mTORC1 is activated through loss of both phosphorylation-dependent activation of TSC2 and direct inactivation of mTORC1. mTORC1 promotes anabolic growth through stimulation of proteins, nucleotides, and lipid biosynthesis as well as inhibition of catabolic processes such as autophagy (through inhibition of ULK1 and TFEB). mTORC1 promotes protein translation through phosphorylation of its downstream substrates S6K1 and 4E-BP1 (leading to activation of S6K and inhibition of 4EBP). mTORC2 is mainly activated by extracellular stimuli such as growth factors; together with AKT, it promotes cell survival and proliferation through phosphorylation of key downstream substrates (activation of AKT, SGK1, and PKC and inhibition of MST1). Phosphorylation of AKT by mTORC2 enhances its activity, and mTORC2 activation is at least partially mediated by PI3K-dependent PIP3 production. 4EBP, eIF4E-binding protein; AMPK, AMP-activated protein kinase; AKT/PKB, protein kinase B; IRS1/2, insulin receptor substrate 1 and 2; MST1, mammalian STE20-like kinase 1; mTORC1/2, mechanistic target of rapamycin complex 1 and 2; PDK1, phosphoinositide-dependent kinase 1; PI3K, phosphoinositide 3-kinase; PIP3, phosphotidylinositol (3,4,5)-trisphosphate; PKC, Protein kinase C; Rag, Ras-related GTPase; Rheb, Ras homolog enriched in brain; S6K1, ribosomal S6 kinase 1; SGK1, Serum/Glucocorticoid Regulated Kinase 1; TFEB, transcription factor EB; TSC1/2, tuberous sclerosis protein complex 1 and 2; ULK1, UNC-5 like autophagy activating kinase 1. Cell Metabolism 2018 27, 314-331DOI: (10.1016/j.cmet.2017.11.004) Copyright © 2017 Elsevier Inc. Terms and Conditions

Figure 2 Kinetic Model of mTORC1 Signaling in β cells (A) Illustration of the hypothesized relationship between mTORC1 activation and metabolic output. Short term and transient mTORC1 activation (green line) correlates with nutrient or growth factor stimulation of β cell replication, anabolic growth, and insulin secretion under physiological conditions. Chronic hyperactivation of mTORC1 (red line) triggered by continued overnutrition correlates with defective insulin secretion, ER stress, and impaired β cell survival under diabetic conditions. (B) The effect of mTORC1 hyperactivation on pancreatic β cell mass and metabolic parameters in β-TSC2-KO mice (with constitutive activation of mTORC1) over time. Mice show increased β cell mass, hyperinsulinemia, and improved glucose homeostasis in the early phase of their life, but they become hyperglycemic and severely hypoinsulinemic due to a dramatic loss of β cells at an older age. Representative pancreatic sections from 6- and 40-week-old β-TSC2-KO mice immunostained with insulin (red) and glucagon (green) are shown. Scale bars, 50 μm. Reproduced from Shigeyama et al. (2008) with permission. ER, endoplasmic reticulum; β-TSC2-KO, β cell-specific TSC2 knockout; TSC1/2, tuberous sclerosis protein complex 1 and 2. Cell Metabolism 2018 27, 314-331DOI: (10.1016/j.cmet.2017.11.004) Copyright © 2017 Elsevier Inc. Terms and Conditions

Figure 3 mTORC1-S6K-Mediated Negative Feedback Loops (A–D) mTORC1 controls several negative feedback loops that regulate RTK-IRS1/2-PI3K and mTORC2 signaling via (A) direct inhibition of IRS1/2, (B) Grb10-dependent inhibition of IRS1/2, (C) S6K1-mediated inhibition of mTORC2 through Rictor, and (D) S6K1-mediated inhibition of mTORC2 through Sin1. (E) mTORC1-S6K1-mediated negative loops constitute intracellular regulatory mechanisms controlling cell growth and homeostasis through restraining excessive actions of insulin and mTORC2 signaling under physiological conditions. (F) Chronic mTORC1-S6K1 hyperactivation triggered by obesity and nutrient overload (elevated glucose, FFAs and amino acids as well as hyperinsulinemia) initiates feedback mechanisms which—in the long run—attenuate insulin and mTORC2 signaling that then could result in diminished functional β cell mass and development of T2D. AKT/PKB, protein kinase B; FFA, free fatty acids; Grb10, growth-factor-bound protein 10; IRS1/2, insulin receptor substrate 1 and 2; mTORC1/2, mechanistic target of rapamycin complex 1 and 2; PI3K, phosphoinositide 3-kinase; Rag, Ras-related GTPase; Raptor, regulatory-associated protein of mTOR; Rictor, rapamycin-insensitive companion of mTOR; RTK, receptor tyrosine kinase; S6K1, ribosomal S6 kinase 1; Sin1-MAPKAP1, mitogen-activated protein kinase-associated protein; T2D, type 2 diabetes. Cell Metabolism 2018 27, 314-331DOI: (10.1016/j.cmet.2017.11.004) Copyright © 2017 Elsevier Inc. Terms and Conditions

Figure 4 mTORC1-Dependent Regulation of Autophagy In the healthy β cell, autophagy is tightly regulated by AMPK-mTORC1 signaling pathways in response to nutrient stimuli (e.g., glucose, amino acids), ensuring proper insulin secretion and glucose homeostasis. In T2D, dysregulation of AMPK-mTORC1 signaling likely contributes to the β cell failure. Prolonged overabundance of nutrients leads to chronic AMPK suppression as well as mTORC1 activation, consequently leading to progressive deterioration of the protective autophagy mechanism in β cells, which will disrupt insulin secretion and energy homeostasis. AMPK, AMP-activated protein kinase; mTORC1/2, mechanistic target of rapamycin complex 1 and 2; T2D, type 2 diabetes. Cell Metabolism 2018 27, 314-331DOI: (10.1016/j.cmet.2017.11.004) Copyright © 2017 Elsevier Inc. Terms and Conditions